Open Label, Sequential-dose Study of PA5108 Latanoprost FA SR Ocular Implant for Mild-moderate Glaucoma

Prior treatment

• Recent surgery in the study eye surgery (including laser).
• Known sensitivity to any component of the product (e.g. latanoprost or polytriazole sensitivity), or to topical therapy used during course of study (e.g. povidone iodine, or anaesthetics).
• Ocular medication in either eye of any kind within 30 days of screening.

Other illness

• Have pseudoexfoliation or pigment dispersion component, history of angle closure, or narrow angles.
• Have a history of or current ocular inflammation.
• Clinically significant ocular disease in either eye (e.g., corneal oedema, uveitis, severe keratoconjunctivitis sicca or infection) which might interfere with the study.
• Any other clinically significant disease (as determined by physician) which might interfere with the study.

Other

• Participants who:
• Have aphakic eyes or only one eye.
• Central corneal thickness in either eye that is less than 470 µm or greater than 630 µm at screening (or a difference between the eyes \>70 µm).
• Any abnormality in either eye preventing reliable applanation tonometry, including aphakic eyes or significant corneal guttatae.

• Participants who:
• Diagnosis of primary open angle glaucoma.
• Unmedicated 8:00am IOP ≥ 24 mmHg and ≤ 36mmHg in the intent to treat eye. Additionally, the IOP at 12:00 and 16:00 hrs must be ≥ 20mmHg and ≤ 36mmHg.
• Corrected visual acuity in each eye greater than or equal to +0.3logMAR.
• Minimum central endothelial cell density of greater than or equal to 1600 cells per mm2
• Currently managing their POAG with IOP lowering drop therapy.